Modality
mAb
MOA
Anti-Tau
Target
BET
Pathway
JAK/STAT
SCD
Development Pipeline
Preclinical
Aug 2025
→ Jan 2027
PreclinicalCurrent
NCT05686249
704 pts·SCD
2025-08→2027-01·Terminated
704 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2010mo awayInterim· SCD
Trial Timeline
Q42026Q2Q3Q42027
Preclinical
Termina…
Catalysts
Interim
2027-01-20 · 10mo away
SCD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05686249 | Preclinical | SCD | Terminated | 704 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| 207-5197 | Samsung Biologics | Approved | BET |